Melatonin: characteristics, concerns, and prospects. J Biol Rhythms
2005; 20: 291–303.
Wehr, TA, Duncan, WC Jr, Sher, L, Aeschbach, D, Schwartz, PJ, Turner, EH, Postolache, TT, Rosenthal, NE.
A circadian signal of change of season in patients with seasonal affective disorder. Arch Gen Psychiatry
2001; 58: 1108–14.
Rajaratnam, SMW, Arendt, J.
Health in the 24-hour society. Lancet
2001; 358: 999–1005.
Dijk, DJ, Lockley, SW.
Integration of human sleep-wake regulation and circadian rhythmicity (Invited Review). J Appl Physiol
2002; 92: 852–62.
Lewy, AJ, Lefler, BJ, Emens, JS, Bauer, VK.
The circadian basis of winter depression. Proc Natl Acad Sci USA
2006; 103: 7414–9.
Rajaratnam, SM, Middleton, B, Stone, BM, Arendt, J, Dijk, DJ.
Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol
2004; 561 (Pt 1): 339–51.
Serfaty, MA, Osborne, D, Buszewicz, MJ, Raven, PW.
The effects of exogenous melatonin in major depression. Chronobiol Int
2003; 20: 1191–3.
Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med
2007; 8 (suppl 3): 34–42.
Nickelsen, T, Samel, A, Vejvoda, M, Wenzel, J, Smith, B, Gerzer, R.
Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: results of a placebo-controlled trial. Chronobiol Int
2002; 19: 915–36.
Zemlan, FP, Mulchahey, JJ, Scharf, MB, Mayleben, DW, Rosenberg, R, Lankford, A.
The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry
2005; 66: 384–90.
Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol
2006; 16: s633–8.
Olie, JP, Kasper, S.
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol
2007; 10: 661–73.
Lemoine, P, Guilleminault, C, Alvarez, E.
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry
2007; 68: 1723–32.
Effective management of depressed mood with agomelatine, a melatonergic antidepressant
2007; 22 (suppl 1): s91.
Hirai, K, Kita, M, Ohta, H, Nishikawa, H, Fujiwara, Y, Ohkawa, S, Miyamoto, M.
Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms
2005; 20: 27–37.
Borja, NL, Daniel, KL.
Ramelteon for the treatment of insomnia. Clin Ther
2006; 28: 1540–55.
Vachharajani, NN, Yeleswaram, K, Boulton, DW.
Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci
2003; 92: 760–72.
Rajaratnam, SM, Polymeropoulos, MH, Fisher, DM, Roth, T, Scott, C, Birznieks, G, Klerman, EB.
Randomised controlled trials of the melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep time shift. Lancet, in press.